Results 71 to 80 of about 786,314 (373)

Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system

British Journal of Clinical Pharmacology, 2022
Proprotein convertase subtilisin/kexin type (PCSK9) inhibitor is a new drug class approved for treating dyslipidemias. Herein, we aimed to investigate the safety profiles of PCSK9 inhibitors (alirocumab and evolocumab) using the Food and Drug ...
Chunmei Ji, Jinmei Bai, Jian-cheng Zhou, Y. Zou, Mingming Yu   +4 more
semanticscholar   +1 more source

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2022
Triazole antifungal drugs (TAD) are widely used to treat invasive fungal infections due to their broad antifungal spectrum and low toxicity. Despite their preference in the clinic, multiple Adverse Events (AE) are still reported each year.
Jianxing Zhou, Zipeng Wei, Baohua Xu, Maobai Liu, Ruichao Xu, Xuemei Wu   +5 more
semanticscholar   +1 more source

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. [PDF]

, 2017
Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of ...
Abagyan, Ruben, Atayee, Rabia, Cohen, Isaac V, Makunts, Tigran   +3 more
core   +2 more sources

COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS)

BMC Women's Health, 2022
Background In reports of adverse reactions following vaccination with the coronavirus disease 2019(COVID-19) vaccines, there have been fewer reports of concern for menstrual disorders in female.
Bing Zhang, Xiao Yu, Jinxing Liu, Jinbao Liu, P. Liu   +4 more
semanticscholar   +1 more source

Circulating histones as clinical biomarkers in critically ill conditions

FEBS Letters, EarlyView.
Circulating histones are emerging as promising biomarkers in critical illness due to their diagnostic, prognostic, and therapeutic potential. Detection methods such as ELISA and mass spectrometry provide reliable approaches for quantifying histone levels in plasma samples.
José Luis García‐Gimenez, Juan Carlos Ruiz‐Rodríguez, Ricard Ferrer, Raquel Durá, Antonio Artigas, Iván Bajaña, David Bolado López de Andujar, Irene Cánovas‐Cervera, Adrián Ceccato, Luis Chiscano‐Camón, Elena Climent‐Martinez, Georgia García Fernández, Gemma Goma, Verónica Monforte, Beatriz Quevedo‐Sánchez, Adolf Ruiz‐Sanmartín, Antonio Sierra‐Rivera, Nieves Carbonell Monleón   +17 more
wiley   +1 more source

Evidence and Extrapolation: Mechanisms for Regulating Off-Label Uses of Drugs and Devices [PDF]

, 2014
A recurring, foundational issue for evidence-based regulation is deciding whether to extend governmental approval from an existing use with sufficient current evidence of safety and efficacy to a novel use for which such evidence is currently lacking ...
Abbott, Ryan, Ayres, Ian
core   +3 more sources

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system

Frontiers in Pharmacology
BackgroundMaribavir and valganciclovir are pharmacotherapeutic options utilized in the management of cytomegalovirus (CMV) infection post-transplantation.
Haolin Teng, Shengnan Zhang, Jinyu Yu, Faping Li   +3 more
doaj   +1 more source

Single‐cell insights into the role of T cells in B‐cell malignancies

FEBS Letters, EarlyView.
Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley   +1 more source

Prototype of running clinical trials in an untrustworthy environment using blockchain. [PDF]

, 2019
Monitoring and ensuring the integrity of data within the clinical trial process is currently not always feasible with the current research system.
Bhattacharya, Sanchita, Butte, Atul J, Wong, Daniel R   +2 more
core   +3 more sources

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax

PLoS ONE, 2022
Background Venetoclax (VEN) is the first selective small molecule Bcl-2 inhibitor approved by FDA and used in adult chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and some acute myeloid leukemia (AML).
Yang Yang, Yamin Shu, Guosong Chen, Yanchao Yin, Fei Li, Juan Li   +5 more
semanticscholar   +1 more source